Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 328-333

  Marder, Stephen R ^a,s   Alphs, Larry ^b   Anghelescu, Ion George ^u   Arango, Celso ^d   Barnes, Thomas R E ^e   Caers, Ivo ^c   Daniel, David G ^f,t   Dunayevich, Eduardo ^g   Fleischhacker, W Wolfgang ^h   Garibaldi, George ⁱ   Green, Michael F ^a,s   Harvey, Philip D ^j   Kahn, René S ^k   Kane, John M ^l   Keefe, Richard S E ^m   Kinon, Bruce ⁿ   Leucht, Stefan ^o   Lindenmayer, Jean Pierre ^p   Malhotra, Anil K ^k,l   Stauffer, Virginia ⁿ   Umbricht, Daniel ⁱ   Wesnes, Keith ^f   Kapur, Shitij ^q   Rabinowitz, Jonathan ^r   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Bracket Global   (United States)

^g AMGEN INC   (United States)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^l ZUCKER HILLSIDE HOSPITAL   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ ELI LILLY AND COMPANY   (United States)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p NEW YORK UNIVERSITY   (United States)

^q KING'S COLLEGE LONDON   (United Kingdom)

^r BAR ILAN UNIVERSITY   (Israel)

^s Geriatric Research Education   (United States)

^t Bracket   (United States)

^u Private Mental Hospital Dr Med Kurt Fontheim   (Germany)

more..

Author keywords

Apathy; Negative symptoms; Schizophrenia

Indexed keywords

ANHEDONIA; APATHY; AUDITORY HALLUCINATION; CHRONICITY; CLINICAL TRIAL (TOPIC); DELUSION; DEPRESSION; EXTRAPYRAMIDAL SYNDROME; FUNCTIONAL ASSESSMENT; GROUPS BY AGE; HUMAN; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT SELECTION; POSITIVE SYNDROME; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REVIEW; REWARD; STUDY DESIGN; TREATMENT DURATION;

APATHY; NEGATIVE SYMPTOMS; SCHIZOPHRENIA;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 84886283569     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.07.058     Document Type: Review

References (21)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. Alphs L., Panagides J., Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. Psychopharmacol. Bull. 2007, 40:41-53.
3. Bobes J., Arango C., Garcia-Garcia M., Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J. Clin. Psychiatry 2010, 71:280-286.
4. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiatry 1995, 166:68-72.
5. Fenton W.S., McGlashan T.H. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am. J. Psychiatry 1994, 151:351-356.
6. Gold J.M., Waltz J.A., Matveeva T.M., Kasanova Z., Strauss G.P., Herbener E.S., Collins A.G., Frank M.J. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Arch. Gen. Psychiatry 2012, 69:129-138.
7. Gozdzik-Zelazny A., Borecki L., Pokorski M. Depressive symptoms in schizophrenic patients. Eur. J. Med. Res. 2011, 16:549-552.
8. Green M.F., Nuechterlein K.H., Kern R.S., Baade L.E., Fenton W.S., Gold J.M., Keefe R.S., Mesholam-Gately R., Seidman L.J., Stover E., Marder S.R. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am. J. Psychiatry 2008, 165:221-228.
9. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967, 6:278-296.
10. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
11. Kirkpatrick B., Buchanan R.W., Breier A., Carpenter W.T. Depressive symptoms and the deficit syndrome of schizophrenia. J. Nerv. Ment. Dis. 1994, 182:452-455.
12. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
13. Leucht S., Pitschel-Walz G., Engel R.R., Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 2002, 159:180-190.
14. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
15. Marder S.R., Daniel D.G., Alphs L., Awad A.G., Keefe R.S. Methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37:250-254.
16. Moller H.J. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251:217-224.
17. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 2001, 27:235-245.
18. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 2012, 137:147-150.
19. Rapado-Castro M., Soutullo C., Fraguas D., Arango C., Paya B., Castro-Fornieles J., Gonzalez-Pinto A., Parellada M., Graell M., Baeza I., Bombin I. Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale. J. Clin. Psychiatry 2010, 71:327-337.
20. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007, 27:2979-2986.
21. Stauffer V.L., Song G., Kinon B.J., Ascher-Svanum H., Chen L., Feldman P.D., Conley R.R. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr. Res. 2012, 134:195-201.